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Background: A key goal for HIV-1 envelope immunogen design is the induction of cross-reactive neutralizing
antibodies (nAbs). As AIDS vaccine recipients will not be exposed to strains exactly matching any immunogens
due to multiple HIV-1 quasispecies circulating in the human population worldwide, heterologous SHIV challenges
are essential for realistic vaccine efficacy testing in primates. We assessed whether polyclonal IgG, isolated from
rhesus monkeys (RMs) with high-titer nAbs (termed SHIVIG), could protect RMs against the R5-tropic tier-2
SHIV-2873Nip, which was heterologous to the viruses or HIV-1 envelopes that had elicited SHIVIG.
Results: SHIVIG demonstrated binding to HIV Gag, Tat, and Env of different clades and competed with the
broadly neutralizing antibodies b12, VRC01, 4E10, and 17b. SHIVIG neutralized tier 1 and tier 2 viruses, including
SHIV-2873Nip. NK-cell depletion decreased the neutralizing activity of SHIVIG 20-fold in PBMC assays. Although
SHIVIG neutralized SHIV-2873Nip in vitro, this polyclonal IgG preparation failed to prevent acquisition after repeated
intrarectal low-dose virus challenges, but at a dose of 400 mg/kg, it significantly lowered peak viremia (P = 0.001).
Unexpectedly, single-genome analysis revealed a higher number of transmitted variants at the low dose of
25 mg/kg, implying increased acquisition at low SHIVIG levels. In vitro, SHIVIG demonstrated complement-mediated
Ab-dependent enhancement of infection (C’-ADE) at concentrations similar to those observed in plasmas of RMs
treated with 25 mg/kg of SHIVIG.
Conclusion: Our primate model data suggest a dual role for polyclonal anti-HIV-1 Abs depending on plasma levels
upon virus encounter.
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Although antibody (Ab)-mediated immunity against
HIV-1 has been the focus of intense research, the role of
Abs in preventing HIV-1 infection remains to be fully
elucidated. The RV144 vaccine trial showed moderate
efficacy (31.2%) and raised the possibility that non-
neutralizing Abs may be associated with protection
against HIV-1 acquisition [1]. In this regard, a biologic-
ally relevant non-human primate model, in which
macaques are passively immunized with Abs against
simian-human immunodeficiency virus (SHIV) followed
by repeated mucosal challenges with a heterologous R5
SHIV at low doses, may mimic key aspects of HIV-1
transmission among humans and thus play an important
role in dissecting the mechanism(s) of Ab action in
HIV-1 transmission and its prevention [2]. Another
consideration in modeling natural infection in humans
is the nature of transmitted HIV-1 strains: most
such viruses are relatively difficult to neutralize (tier 2
neutralization phenotype).
Early attempts to use primates to elucidate the role of
Abs were conducted with polyclonal IgG isolated from
HIV-1-infected subjects (termed HIVIG) and showed
either no or complete protection against laboratory-
adapted, neutralization-sensitive (tier 1) viruses in
chimpanzees depending on challenge virus doses [3-5].
Anti-HIV-1 envelope (Env) Abs have also been evaluated
in rhesus monkeys (RMs) challenged with SHIVs encod-
ing HIV-1 env, tat, rev and vpu. SHIVs allow assessing
the protective role of broadly neutralizing anti-HIV-1
monoclonal Abs (bnmAbs) by passive immunization
[reviewed in [2]]. Of note, SHIVs used earlier, such as
SHIV89.6P, were either X4- or dual-tropic and irreversibly
destroyed naïve and memory CD4+ T cells within
two weeks [6]. When HIVIG alone or combined with
bnmAbs was tested against SHIV89.6PD [7,8], only the
combination of HIVIG with bnmAbs resulted in moder-
ate prevention of virus acquisition. In another pilot
study, polyclonal IgG isolated from HIV-1-infected
chimpanzees was administered to macaques that were
challenged with homologous SHIV. Only two out of 10
macaques remained aviremic, one treated with high-
dose IgG and the other one challenged with a low dose
of virus [9].
Early passive immunization studies in primates were
performed with single high-dose, intravenous virus chal-
lenges rather than low-dose mucosal virus exposures
that more closely resemble sexual HIV-1 transmission
among humans. Recently, a passive immunization study
using a combination of polyclonal IgG and bnmAbs was
performed against repeated low-dose challenges with the
tier 2 R5-tropic SHIVSF162P3; virus acquisition could not
be prevented even though the challenge virus was hom-
ologous to the polyclonal IgG given [10].We have constructed SHIV-2873Nip, an R5-tropic
SHIV carrying a HIV-1 clade C (HIV-C) env isolated
from a Zambian infant who had rapid disease progres-
sion and died within 1 year of birth [11]. SHIV-2873Nip,
a tier 2 virus, causes AIDS in RMs with clinical parame-
ters and a disease progression rate similar to those
in humans (unpublished data). Thus, the RM/SHIV-
2873Nip model is a biologically relevant system to assess
the role of Abs in providing protection against lentiviral
acquisition.
Here we report passive immunization with SHIVIG, a
polyclonal preparation of IgG isolated from RMs chron-
ically infected with clade C SHIV strains carrying enve-
lopes phylogenetically distinct from that of the challenge
virus. We tested whether SHIVIG could protect RMs
against multiple low-dose intrarectal (i.r.) challenges
with SHIV-2873Nip that is heterologous to any viruses
or envelopes against which the IgG responses had been
elicited. We elected to perform upfront heterologous
SHIV challenges to mimic the situation of human AIDS
vaccine recipients, who are not likely to be exposed to
HIV-1 strains that exactly match the composition of the
immunogen(s). Thus, our passive immunization study in
the primate model was designed to assess the level of
cross-neutralizing IgG needed for in vivo protection;
such information would be helpful to guide future devel-
opment of Ab-based immunogens. Unexpectedly, virus
acquisition was not prevented at any SHIVIG dose. Ra-
ther, we found evidence of partial inhibition of acute
viremia or increased virus acquisition, depending on the
SHIVIG dose.
Results
Selection of RM donors and isolation of total IgG
We selected RMs with high neutralizing antibody (nAb)
titers against several viruses (Table 1). We had used these
animals in previous virus adaptations, titrations, and vac-
cine studies [12-14]. All animals were chronically infected
with SHIV-1157ip [12] and/or SHIV-1157ipd3N4 [15];
some monkeys had also been vaccinated (Additional file 1:
Table S1) or challenged with Schistosoma mansoni, which
the animals cleared after the acute stage of parasite infec-
tion [13]. Four RMs were long-term non-progressors.
Some RMs developed Abs that neutralized heterologous
viruses at high titers (Table 1). Sera collected sequentially
from such SHIV-infected RMs were used to isolate total
IgG; the final preparation was named SHIVIG (Methods).
SHIVIG binding specificity and in vitro neutralization
potency
By ELISA, SHIVIG cross-recognized HIV-1 gp120 and
gp140 of clades A, B and C, but did not bind to clade D
Env. Anti-Gag binding activity was comparable to that
against Env whereas level of Abs against HIV-1 Tat was
Table 1 Neutralizing antibody titers of rhesus monkeys selected as SHIVIG donors
RM Homologous clade C viruses Heterologous clade C viruses Heterologous clade B viruses
SHIV-1157ip (early, tier 1) SHIV-1157ipd3N4 (late, tier 2) HIVZM135M HIV1084i HIVpIndieC HIVZM233M.PB6 HIVZM109F SHIV-2873Nip SHIVSF162P3 HIVSF162.LS HIVNL4-3 SHIV89.6P
RAo-8 2,048 >640 <20 128 42 <20 >640 <40 220 32
RCt-10 360 >640 >640 6,500
RHo-10 250 >640 >640
RHy-9 600 >10,240 <20 100 90 <20 <20 >640 173 100
RJa-9 1,800 >10,240 <20 128 59 22 2,048 68 35,770 128
RLu-9 >1,280 >640 <20 50 47 <20 <20 >640 58 75
RMf-9 2,048 >640 <20 128 <20 35 >640 78 18,303 128
RPo-10 200 >640 >640
RTs-7 2,048 >640 128 >640 32
NAb titers (reciprocal dilution of sera giving 50% reduction in virus replication) were determined in TZM-bl cells or, for SHIV-1157ipd3N4 and SHIV-2873Nip, in human PBMC-based assays. The SHIVs were prepared in
RM PBMC; HIV1084i, HIVNL4-3 and HIVpIndieC were prepared in human PBMC; nAb titers against the remaining HIV strains were performed using pseudoviruses generated in transfected 293 T cells. All neutralization assays
were performed at least in duplicate.
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http://www.retrovirology.com/content/11/1/8low (Figure 1A). Competition ELISA with bnmAbs b12,
VRC01, 4E10 and 17b demonstrated the presence of Abs
directed against the CD4-binding site, the CD4-inducible
site and the membrane-proximal external region (MPER)
of gp41, respectively (Figure 1B). Detailed analysis of anti-
Env binding with consensus clade C gp120 peptides re-
vealed Abs reacting with V1 and V3 and the C5 region
(Figure 1C). Within gp41, SHIVIG interacted with the
immunodominant region (IDR), the C-terminal heptad
region (CH), an undefined region between IDR and CH as
well as with the intracellular portion. Thus, SHIVIG dem-
onstrated antigen specificity similar to plasma samples
from HIV-1-infected subjects [16].
Next, SHIVIG was tested for neutralization potency
against tier 1 and tier 2 viruses (Table 2). While SHIVIG
efficiently neutralized all three tier 1 viruses, neutralization
of tier 2 strains was less potent: only two out of seven such
viruses tested, including SHIV-2873Nip, were neutralized at1 2 3 4
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Figure 1 SHIVIG characterization. A. SHIVIG binding to soluble HIV and S
plates and probed with serial dilutions of SHIVIG. Binding was detected as
(n = 3). Env proteins were derived from the following HIV or SHIV strains: clade
ELISA with the CD4-binding site-specific bnmAbs b12 and VRC01; gp41 MPER
Plates were coated with HIV-1CN54 gp120 for b12 and VRC01 analysis or SHIV-
indicated along with different concentrations of SHIVIG in duplicates or triplic
anti-gp120 Abs coated on the plate and the assay was continued as describe
which is determined as the reading without SHIVIG (100% binding is mark
naïve RM IgG were used as negative controls (not depicted). C. ELISA of S
pools of peptides assigned to HIV-1 Env regions. Dotted line represents ba
gp41; CH, C-terminal heptad region; TMR, transmembrane region. Each dat
repeated at least twice.60% efficiency. To establish the neutralization potency of
SHIVIG against the intended heterologous challenge SHIV-
2873Nip in a more relevant assay, we performed human
peripheral blood mononuclear cell (PBMC)-based assays
with cells obtained from several donors. Neutralization of
SHIV-2873Nip was as high as 95% (1 mg/ml SHIVIG). The
half maximal inhibitory concentration (IC50) values ranged
from 0.2 to 144 μg/ml (mean, 11.9 μg/ml) depending on
the donor, a variability that is likely due to the inherent he-
terogeneity of PBMC from different donors, including
natural killer (NK) cell receptor polymorphism [17].
In vitro SHIVIG effector functions
Increasing evidence suggests a role of NK cells in early
antiviral defenses, including HIV-1 [18]. We performed
PBMC-based neutralization assays with/without NK cells
(Figure 2A). The virus/Ab mixture was left with the
PBMC until day 4, thus allowing for ADCC activity.-1 0 1 2 3
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IV proteins was tested by ELISA. Proteins were captured on the
described in Methods. Each data point represents the mean ± SEM
A, UG37; B, BaL; C, CN54 and SHIV-1157ip; D, UG21. B. Competitive
-specific bnmAb 4E10; and CD4-inducible site-specific bnmAb 17b.
1157i gp160 for 4E10 and further incubated with 0.5 μg/ml of the bnmAb
ates. For 17b mAb, HIV-1CN54 gp120 was captured by polyclonal sheep
d in Methods. The y-axis indicates OD percentage of maximal binding,
ed by dashed line). The irrelevant mAb Fm-6 (anti-SARS virus) and
HIVIG with consensus clade C Env peptides. The x-axis designates
ckground. IDR, immunodominant region; UDR, undefined region in
a point represents the mean ± SEM (n = 3). All experiments were
Table 2 Percent neutralization of different virus strains
by SHIVIG in TZM-bl cell-based assay
Virus Clade Tier SHIVIG bPositive control
KNH1088.ec5 A 2 0 83
SF162 PV B 1 94 100
BaL.ec1 B 1 92 99
GS015.ec12 C 1 74 95
GS 014 IMC C 2 0 82
E0836M4.ec3 D 2 0 80
CM235.ec5 AE 2 66 100
GS 020 IMC AE 2 0 38
55815.ec3 AG 2 0 75
SHIV-2873Nip C 2 a58 c56
SHIVIG was tested at 0.5 mg/ml, except where noted. aNeutralization obtained
with 1 mg/ml of SHIVIG. bAn HIV-positive serum pool was used as positive
control, except as indicated. cBnmAb VRC01 (50 μg/ml) was used as positive
control. IMC, infectious molecular clone. All neutralization assays were
performed at least in duplicate.
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Figure 2 In vitro neutralization and effector functions of SHIVIG again
SHIVIG in PBMC assays with or without NK cells. Serially diluted SHIVIG was
of NK cells (blue) in triplicates. VRC01 was used as a positive control and w
PBMC depleted of NK cells (dashed grey line) as described in Methods. B. A
donors; positive control; squares) was assessed against SHIV-2873Nip as
inhibition (y axis) by increasing concentrations of SHIVIG (red) or HIVIG
same concentrations. C. ADCC activity of serially diluted SHIVIG (red) and
target cells coated with gp120 of HIV96ZM651 (clade C) and human PBMC a
in the presence of increasing concentrations of SHIVIG or SHIVIG-Fab. Exp
are shown.
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http://www.retrovirology.com/content/11/1/8NK-cell depletion led to a significant decrease of
neutralization potency of SHIVIG, characterized by a
20-fold increase of IC50 value from 2.2 μg/ml (PBMC) to
42 μg/ml (PBMC minus NK cells); virus neutralization
by VRC01 was not affected.
SHIVIG almost completely inhibited the challenge
virus at 0.2 mg/ml in the ADCVI assay performed with
CEM.NKr.CCR5 target cells and human PBMC as
effector cells (Figure 2B). To measure ADCC (Figure 2C),
the same target cells were coated with clade C HIV96ZM651
gp120; PBMC were used as effector cells. We could not
reach >35% target cell killing, possibly due to imperfect
recognition of the heterologous gp120 on the cell surface
by SHIVIG.Animal study design and SHIVIG pharmacokinetics
Next, we passively immunized RMs with three different
doses of SHIVIG against weekly low-dose i.r. SHIV-
2873Nip challenges (Figure 3A). Group 1 RMs received
SHIVIG at 400 mg/kg, Group 2 at 675 mg/kg, and
Group 3 at 25 mg/kg. Control Group 4 macaques wereSHIVIG in PBMC NK
VRC01 in PBMC NK
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as analyzed with unfractionated human PBMC (solid grey line) and
DCVI activity of SHIVIG and HIVIG (IgG from a pool of HIV-positive
described in Methods. The graph shows the percentage of virus
(grey) normalized by values obtained for negative controls at the
SHIVIG-derived Fab (grey) were tested in triplicates with CEM-NKr
s effector cells. The graph shows killing (in percentage) of target cells
eriments were repeated in triplicate, and representative mean results
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Figure 3 Study design and SHIVIG pharmacokinetics. A. Animal study design and timeline. Four groups of female RMs were enrolled. Group
1 (n = 6) received 400 mg/kg of SHIVIG, Group 2 (n = 2), 675 mg/kg, and Group 3 (n = 6), 25 mg/kg, respectively. Group 4 (n = 14) RMs served
as virus-only controls. Ten animals were enrolled and four additional animals used for virus titration given the identical virus dose served as
additional controls. The challenge virus, SHIV-2873Nip, had been titrated i.r. to yield systemic infection (>104 viral RNA copies) in untreated
monkeys after a maximum of 5 weekly challenges (small red arrows); the challenge dose was 5,000 50% tissue culture infectious doses (TCID50)
measured by TZM-bl assay. SHIVIG infusions (large blue arrows) as well as viral challenges were stopped after the monkeys became viremic
(>104 viral RNA copies/ml). B. The number of SHIVIG administrations that RMs from different groups received while their vRNA loads were
<104 copies/ml. C-E. SHIVIG pharmacokinetics in RM groups. Large blue arrows indicate biweekly SHIVIG administrations and small red arrows
indicate SHIV-2873Nip challenges; C. Group 1 (400 mg/kg of SHIVIG, n = 6). D. Group 2 (675 mg/kg of SHIVIG, n = 2); E. Group 3 (25 mg/kg of
SHIVIG, n = 6). The insert represents the same graph showing the lower Y axis range. Serial dilutions of RM plasmas were incubated on ELISA
plates to which HIV-1 BaL gp120 had been added and preimmobilized. Binding was assessed as described in Methods. All samples were assayed
in triplicate.
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http://www.retrovirology.com/content/11/1/8left untreated. Macaques with different MHC and TRIM
5α genotypes were distributed approximately evenly
(Additional file 2: Table S2). SHIVIG was administered
intravenously every two weeks, 24 h before the first, third
and fifth low-dose viral challenges. A maximum of three
SHIVIG administrations was given. All RMs were
challenged i.r. weekly with low-dose SHIV-2873Nip
(Figure 3A). SHIVIG infusions (Figure 3B) as well as viral
challenges were stopped once an animal had >104 vRNA
copies/ml, a level typically associated with subsequent
seroconversion and hence persistent systemic infection.
SHIVIG plasma levels were measured by ELISA with
gp120 as antigen (Figure 3C-E). SHIVIG had a biphasic
decay with an initial drop during the first 24 h and a mean
half-life of 12.2 ± 1.8 days after the last administration.
These values are compatible with those observed by others
for HIVIG and nAbs administered i.v. to RMs [7]. The
mean SHIVIG concentration in RM plasma on the day of
first viral challenge was 2.6 ± 0.2 mg/ml for Group 1
(400 mg/kg), 4.6 ± 0.9 mg/ml for Group 2 (675 mg/kg)
and 0.22 ± 0.01 mg/ml for Group 3 (25 mg/kg).
The penetration of SHIVIG into mucosal secretions
was assessed by measuring anti-gp120 binding on day 13
in vaginal washes. The latter were collected because rec-
tal mucosae could not be manipulated during i.r. virus
challenges. In Group 1 RMs, SHIVIG represented 7.6 ±
1.4% of total vaginal IgG (Table 3). SHIVIG concentra-
tion in mucosal secretions of Group 3 (25 mg/kg) was
below the detection limit.SHIV-2873Nip challenges
The repeated low-dose challenges resulted in infection
of all passively immunized RMs (Figure 4A-D), although
SHIVIG neutralized SHIV-2873Nip almost completely
in vitro (Figure 2A). Mean time from initial virus expos-
ure to peak viremia was 3.7 ± 1.4 weeks for Group 1,
two weeks for Group 2, 3 ± 1.6 weeks for Group 3, and
2.7 ± 0.9 weeks for Group 4. These differences were not
statistically significant.Table 3 Percentage of SHIVIG in total vaginal IgG of
Group 1 RMs two weeks after administration
Monkey % SHIVIG
RKg-12 12.4
RKs-12 5.2
RQv-12 8.7
RRm-12 4.3
RVv-12 4.5
RZn-12 10.4
The content of SHIVIG and total RM IgG was determined as described in and
Methods. All samples were analyzed in triplicates.Higher SHIVIG doses demonstrate partial protection
We performed statistical analysis of parameters for
viremia and found no significant differences in the time
to viremia, time to peak viremia and area-under-the-
curve (AUC) between different groups. However, Group
1 monkeys (400 mg/kg) demonstrated significantly lower
peak viral RNA (vRNA) loads compared with control
RMs (P = 0.001) (Figure 4E), indicating that SHIVIG
administered at 400 mg/kg conferred significant partial
protection against SHIV-2873Nip. Although the mean
peak vRNA load of Group 3 (675 mg/kg) was lower
compared with that of the control, statistical significance
was not reached because we could only enroll two RMs.
Statistical analyses did not reveal any correlation between
viremia and MHC or TRIM5α genotypes.
All RMs seroconverted post challenge
All macaques seroconverted by Western blot with HIV-
1/2 proteins and IgM ELISA with SIV Gag and HIV-1
Env as antigens (data not shown). IgM ELISAs were per-
formed to distinguish between SHIVIG-associated titers
that decline with time and Ab responses induced by
breakthrough infection. Notably, three RMs from Group
3 (RNz-11, ROw-11, and RJu-11) developed rapid IgG
responses after day 40 post-challenge and breakthrough
infection (insert, Figure 3E). This observation agrees
with recent reports [10] and indicates that a suboptimal
concentration of virus-specific Abs in plasma at the time
of virus challenge might facilitate the generation of
humoral immune responses to the challenge virus.
SHIV-2873Nip is not completely neutralized by plasma
samples of passively immunized RMs
Next, we assessed whether challenge virus neutralization
by RM plasma after SHIVIG administration was compar-
able to in vitro assay values obtained for SHIVIG itself.
Thus, we measured the neutralizing activity of RM plasma
samples from the day of first virus challenge. All measure-
ments were carried out using human PBMC obtained
from the same individual. From every experimental group,
we selected the animals with the highest and lowest
viremia levels to test whether the differences could be
linked to SHIVIG. IC50 values extrapolated from the
plasma samples were consistent with IC50 values obtained
earlier for the SHIVIG prep (Table 4). None of the plasma
samples completely prevented PBMC infection. Further-
more, no significant differences were observed for IC50
values and percent neutralization for RMs with high ver-
sus low peak vRNA loads. Of note, plasma samples of
Group 3 RMs demonstrated a lower percentage of SHIV-
2873Nip neutralization than those from animals of
Groups 1 and 2. This suggests correlative trends between
the administered dose of SHIVIG, neutralization, and partial
protection against SHIV-2873Nip.
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Figure 4 Plasma viral RNA (vRNA) loads after SHIV-2873Nip challenges. A-D. Graphs represent vRNA loads after viral challenges for Group 1–4,
respectively. Small red arrows indicate 5 low-dose SHIV-2873Nip challenges. Animals in Group 2 B became infected after the second viral challenge
and further challenges were omitted. D. Virus-only controls. Three animals from this group could not be challenged at week 4 (inclement weather
forced closure of the primate center) and one RM (*RSc-12) became viremic only after the high-dose challenge (30,000 TCID50) at week 7 (large red
arrow). During the 2-week interval between the 4th and 5th low-dose challenge, this RM had developed SIV Gag-specific proliferative responses (data
not shown). E. Statistical analysis of the peak of vRNA loads. The dashed line represents the limit of detection (50 copies/ml). For control Group 4, peak
vRNA load was calculated including the animals with protocol breach. Peak viremia levels were compared using negative binomial regression, in order
to adequately model the non-normality of the observed peak levels. Raw p-values from pair-wise comparisons with the control group were adjusted
using Dunn’s method.
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transmitted virus quasispecies
Next, we tested the number of transmitted virus variants
(Figure 5A), using plasma samples collected at peak
viremia. We amplified a 570 bp env fragment spanningthe V1/V2 region. For the final single-genome analysis
(SGA), we obtained and sequenced ≥10 individual clones
per RM as well as 20 for the SHIV-2873Nip stock. Five
quasispecies were observed in the virus stock, whereas
control macaques demonstrated a median of two
Table 4 Neutralization of SHIV-2873Nip by plasma samples of SHIVIG recipients
Group
(mg/kg of SHIVIG)
Monkey Peak
vRNA load (copies/ml)
Day of 1st challenge
Highest % of neutralization SHIVIG plasma IC50 (μg/ml)
Group 1 RVv-12 4,500 90.1 12.9
(400) RQv-12 342,850 85.7 10.9
Group 2 RZu-11 201,700 74.7 (91.8) 6.0
(675) RRs-12 229,600 88.8 (95.6) 4.8
Group 3 RWt-12 61,750 58.5 6.2
(25) RNz-11 1,032,600 66.7 3.3
The highest percent of neutralization was seen at a plasma dilution of 1:6. Values in parentheses represent the highest % of neutralization reached for RZu-11 and
RRs-11 at plasma dilutions 1:54 and 1:18, respectively. SHIVIG plasma IC50 concentrations were determined using the concentration of SHIVIG in RM plasma on
the day of challenge and the dilution of the same plasma sample showing 50% of neutralization in PBMC assay. Neutralization assays were performed at least in
triplicate. Measurements of viral loads were performed in duplicate.
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Group 1 (400 mg/kg) and only one variant for Group 2
(675 mg/kg). In contrast, in Group 3 macaques (25 mg/kg),
the number of variants ranged from two to six with
a median of three variants, which was significantly
different from the median number of quasispecies observed
for the control group (P = 0.032 by Mann–Whitney test
with Holm correction for multiple comparisons). These
results imply increased virus acquisition at the low
SHIVIG dose.1
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used to obtain SHIV-2873Nip, the challenge virus,
through passaging in RMs. NL-LucR.2873Nipd carries
Env from SHIV-2873Nipd, which was isolated from an
animal that developed AIDS and thus represents a late
form of the same virus. SHIVIG enhanced infection of
both viruses when fresh normal human serum was
present as a source of complement (Figure 5B-C).
Infection caused by “early” NL-LucR.2873Ni virus was
enhanced by almost 3-fold, while infection by “late”
NL-LucR.2873Nipd was augmented up to 16-fold. No
significant enhancement was seen when the normal serum
was heat-inactivated to destroy complement. Control IgG
isolated from a naïve RM (nRM) did not show any en-
hancement effect. While SHIVIG at 1.27 mg/ml showed
50% neutralization of NL-LucR.2873Ni in the presence of
fresh serum, NL-LucR.2873Nipd could not be neutralized.
To control whether neutralization could be achieved in
this assay, we tested the tier 1 NL-LucR.1157ipEL that
carries an Env closely related to viruses against which
SHIVIG had been raised (Additional file 1: Table S1). As
shown in Figure 5D, SHIVIG completely neutralized
the tier 1 NL-LucR.1157ipEL in the presence of either
fresh or heat-inactivated complement. Two clade C viruses
(Ce1086 and Du151) from acute, sexually acquired infec-
tions and heterologous to challenge virus were also tested.
SHIVIG enhanced the infection (up to 6-fold) of both
viruses at lower concentrations and neutralized them at
higher concentrations when fresh normal human serum
was present as a source of complement (data not shown).
Do SHIVIG concentrations yielding maximal C’-ADE
in vitro correlate with SHIVIG plasma levels of Group 3
RMs given 25 mg/kg?
The C’-ADE data prompted us to compare SHIVIG con-
centrations that gave the highest degree of enhancement
in the in vitro assay with SHIVIG plasma levels in Group
3 RMs. Among treated macaques, SHIVIG plasma con-
centrations on day 1 and day 8 after the administration
varied between 180 to 250 μg/ml and 70–130 μg/ml,
respectively. The peak of enhancement of infection
with NL-LucR.2873Ni in C’-ADE assay was observed in
the same range of SHIVIG concentrations, 15.7 to
141 μg/ml. This finding strongly suggests an association
between the in vitro observed C’-ADE of infection and
increased virus acquisition in vivo.
Discussion
Passive immunization with polyclonal SHIVIG given to
RMs that were subsequently exposed repeatedly to low
doses of the pathogenic R5 SHIV-2873Nip yielded par-
tial protection at 400 mg/kg as evidenced by statistically
significant lower peak viral RNA loads compared with
control RMs. The SGA data suggest the possibility ofincreased viral acquisition at the low SHIVIG dose of
25 mg/kg. When tested ex vivo in the presence of fresh
complement, low SHIVIG concentrations showed sig-
nificant C’-ADE when tested with viruses carrying enve-
lopes related to the challenge virus or other HIV-Cs.
These results suggest the possibility that the polyclonal
SHIVIG contained Abs with the ability to either partially
protect or to facilitate virus acquisition.
These surprising data were generated in a primate
model that sought to replicate as many aspects of HIV-1
transmission among humans as possible. Specifically, we
chose to perform an upfront heterologous challenge, in
contrast to earlier studies that matched the IgG prepar-
ation with the challenge virus Env [9,10,19,20]. We also
elected to perform multiple low-dose challenges instead
of using a single high-dose of virus. The low-dose chal-
lenge regimen resulted in a low number of transmitted
viral variants in our control animals, a situation similar
to that observed in humans. Lastly, the exclusive R5
tropism of our challenge virus reflects that of acutely
transmitted founder viruses isolated from humans.
Ab-mediated enhancement of HIV-1 acquisition has
been implicated in a recently published subgroup ana-
lysis of the Vax004 AIDS vaccine efficacy trial that
involved gp120 immunogens [21]. This study linked Fcγ
receptor IIIa (FcγRIIIa) genotype with a significantly
increased HIV-1 acquisition rate for vaccinees with low
behavioral risk of infection and homozygosity for the
FcγRIIIa V allele. Other evidence for in vivo increased
viral acquisition following immunization stems from
experiments involving SIV [22], feline immunodeficiency
virus [23-25], and equine infectious anemia virus [26].
Enhancement of viral acquisition and/or higher viral
loads or earlier viremia by pre-existing Abs are well-
known phenomena for dengue virus [27,28], Murray
Valley encephalitis virus [29], respiratory syncytial virus
[30], Ebola virus [31] and measles virus [32].
Another recent report described a passive immuniza-
tion study conducted in HIV-infected pregnant women
and their infants in Uganda with the aim of testing anti-
HIV-1 Ig (termed HIVIGLOB) for its ability to lower the
risk of mother-to-infant virus transmission [33]. Two
groups of pregnant women were enrolled; all mothers
and their infants were treated with single-dose nevira-
pine (NVP) according to standard local protocol. Half of
the women and their children also received HIVIGLOB
(maternal dose, 200 mg/kg at week 36–38 of gestation).
The infants received HIVIGLOB at 400 mg/kg within
18 h of delivery. At birth, 9.1% of infants born to
HIVIGLOB-treated mothers were HIV positive com-
pared with 4.1% of control infants; the difference was
statistically significant. The higher HIV-1 infection rate
of HIVIGLOB-treated infants persisted throughout six
months of follow-up, although differences at later time
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passive immunization with HIVIGLOB did not prevent
HIV-1 acquisition in any infants born to infected mothers,
and may have enhanced in utero HIV-1 transmission.
Ab-mediated increased viral acquisition was also sug-
gested in a recent study of Burton et al. [34], who per-
formed passive immunization with human monoclonal
Abs (mAbs), including the anti-CD4 binding site mAb
b6, which is weakly neutralizing. The latter provided no
protection from virus acquisition when tested against
intravaginal challenge with SHIVSF162P4 (tier 1) or
SHIVSF162P3 (tier 2). SGA revealed a significantly higher
number of newly transmitted quasispecies among the
b6-treated monkeys compared with the control groups,
which is compatible with increased virus acquisition.
Ab-mediated enhancement of lentiviral infection can
occur through different mechanisms. The VAX004 data
implied that increased risks of HIV-1 acquisition oc-
curred through FcγR-mediated enhancement. Such a
mechanism was first described by Takeda and Ennis
[35]. Their studies involving cultured monocytes/
macrophages demonstrated IgG-linked enhancement
of infection only in the presence of surface-expressed
Fc-receptors (FcRs) and the IgG constant region. This
enhancement still required virus entry through CD4,
implying that FcR-bearing cells may enhance infectivity in
trans. The second major mechanism was first described
by Robinson et al., who demonstrated the critical role of
complement in C’-ADE [36]. This activity was found to
be highly prevalent in individuals with acute HIV-1 infection
who had developed binding Abs but no autologous nAbs
yet; strikingly, enhancement of infection reached levels
up to 350-fold and was not only seen with autologous
virus, but also with different virus isolates [37].
Prompted by our observation of an increased number
of quasispecies seen in RMs given the low SHIVIG dose,
we examined this preparation for C’-ADE activity
in vitro. Significant enhancement of infection was seen
at low SHIVIG concentrations, whereas higher concen-
trations of SHIVIG showed some virus-inhibitory acti-
vity, thus providing a potential mechanism for the
increased number of quasispecies seen in the RMs
treated with the low-dose SHIVIG. The complex interac-
tions of HIV-1 with complement, including enhance-
ment of infection, have been reviewed [38]. In this
context, it is worth mentioning the recent suboptimal
outcome of the phase IIb HVTN 505 trial [39]. The
multicomponent immunogens contained envelope and
possibly may have induced low levels of anti-Env Abs.
One of our initial goals for the passive immunization
using the tier 2 SHIV-2873Nip had been to compare
in vivo protection with in vitro neutralization titers of
serum samples collected at the time of virus exposure.
We now realize that the role of Abs directed againstHIV-1/SHIV is more complex in vivo and that the cur-
rently used neutralization assays have a narrow focus on
prevention of virus entry. A more complex interaction
of Abs and virus with primary cells is captured to a
certain degree in PBMC-based assays but only if the
Ab-virus mixture is left with the cells for several days, a
protocol we have followed when assessing SHIVIG
in vitro. In contrast, most neutralization assays include a
washing step, in which the virus-Ab mixture is removed,
thus not allowing ADCC activity to impact the final
readout. Currently, routine neutralization assays do not
query the influence of complement, and their lack of
predictive value may be due to their oversimplified read-
out and lack of probing mechanisms that may influence
the outcome in vivo.
To summarize, passive immunization with SHIVIG
yielded partial protection at higher doses and may have
increased viral acquisition at the low dose – a perplexing
finding. Future studies are required to address the
following questions: Can the Ab-mediated infection-
enhancing activity be separated from protective func-
tions, such as neutralization, ADCVI and ADCC? More
important still, can immunogens be designed that will
elicit protective but not infection-enhancing Abs? Will it
be possible to induce durable nAb responses at sufficiently
high levels to counteract any potential Ab-mediated
enhancement of infection?Conclusions
SHIVIG displayed the key characteristics of human Abs
raised upon HIV-1 infection in humans. Passive immuni-
zation with SHIVIG yielded partial protection at higher
doses and evidence of increased acquisition at the low
dose. Our data imply that the polyclonal SHIVIG prepar-
ation contained Abs with the ability to either protect the
host or to facilitate viral acquisition. These results were
generated in a primate model that replicates as many as-
pects of HIV-1 transmission among humans as possible,
including R5 tropism and a tier 2 neutralization phenotype
of the challenge virus as well low-dose repeated mucosal
challenges with heterologous virus.Methods
Animals
RMs were housed at the Yerkes National Primate Re-
search Center (YNPRC, Atlanta, GA) in accordance with
standards of the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. Animal experi-
ments were approved by the Institutional Animal Care
and Use Committees at Emory University and the
Dana-Farber Cancer Institute (DFCI) via a Collaborating
Institution Animal Use Agreement. Blood was collected
under ketamine or Telazol anesthesia.
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HIV-1 Tat, HIV-1UG37 gp140 (clade A), HIV-1BaL gp120
and HIV-1IIIB gp120 (clade B), HIV-1CN54 gp120 and
HIV-196ZM651 gp120 (clade C) and HIV-1UG21 gp140
(clade D) along with consensus clade C peptides were
kindly provided by the NIH AIDS Research and Refer-
ence Reagent Program. SHIV-1157ip gp120 and gp160
were kindly provided by Dr. S.-L. Hu. SIV Gag was from
Immuno Diagnostics Inc.
SHIVIG preparation
Total IgG was isolated from sera of RMs infected with
SHIV-1157ip [12], SHIV-1157ipd3N4 [15], or related vi-
ruses as published [10]. Heat-inactivated RM sera were
diluted with PBS, IgG was isolated by chromatography
(Protein G Sepharose, GE Healthcare) followed by buffer
exchange to PBS, and concentrated by Amicon ultrafiltra-
tion (50 kDa cut-off membrane, Millipore). All IgG prepa-
rations from individual RMs were analyzed for neutralizing
activity and then combined, concentrated to 26.2 mg/ml,
filter-sterilized and tested for the presence of endotoxin; all
preparations contained <0.02 EU per mg of IgG.
SHIVIG administration
SHIVIG was administered intravenously every two weeks,
24 h before the first, third and fifth low-dose viral chal-
lenges. Group 1 RMs received SHIVIG at 400 mg/kg,
Group 2 at 675 mg/kg, Group 3 at 25 mg/kg, and control
Group 4 macaques were left untreated. A maximum of
three SHIVIG administrations was given. SHIVIG infusions
were stopped once an animal had >104 vRNA copies/ml.
ELISAs
ELISA plates (Nunc) were coated with 1 μg/ml of HIV
proteins in carbonate buffer, pH 9.6. After washing, plates
were blocked with 2% BSA (Sigma-Aldrich), 0.05% Tween-
PBS (blocking buffer). Plates were then incubated with ser-
ial dilutions of SHIVIG in triplicates. After washing, plates
were developed by incubation for 1 h with rabbit anti-
monkey IgG HRP-conjugated Ab (Sigma) and by adding
100 μl of o-phenylenediamine solution.
For competitive ELISA with bnmAbs b12, VRC01 and
4E10, plates were coated with 0.1 μg/ml of HIV-1CN54
gp120. After washing and blocking with blocking buffer,
plates were incubated with b12, VRC01 or 4E10 (0.5 μg/
ml) along with different concentrations of SHIVIG
in duplicates. After extensive washing, plates were incu-
bated for 1 h with biotinylated goat anti-human IgG
(RM IgG adsorbed; Southern Biotech) and 1 h with HRP-
streptavidin (Jackson Immunoresearch). Plates were again
washed, developed with 3,3′,5,5′-tetramethylbenzidine
solution (TMB; Invitrogen).
Competitive ELISA with mAb 17b was performed as
described [40]. In brief, plates were coated with 1 μg/mlof sheep anti-gp120 Ab (Aalto Bio Reagents Ltd.) and
blocked with blocking buffer. HIV-1CN54 gp120 (1 μg/ml)
was incubated with soluble CD4 (40 μg/ml) for 45 mi-
nutes. Then, mixture was diluted 20-fold by blocking buf-
fer, added to plates and incubated for 1.5 h. After washing
bnmAb 17b (0.5 μg/ml) along with different concentration
of SHIVIG was added to the plate. Binding was detected
as described above.
ELISA with consensus clade C peptides was performed
essentially as described above. Plates were coated with
pools of 5 peptides (5 μg/ml for each) in triplicates,
blocked and probed with 5 μg/ml of SHIVIG. To detect
binding, plates were incubated with anti-monkey IgG
HRP-conjugated Ab and developed with TMB solution.
Determination of SHIVIG and total IgG concentrations in
RM samples
The concentration of SHIVIG in plasma samples was
determined by ELISA. The 96-well plates were coated with
gp120 of HIV-1BaL at 0.6 μg/ml for plasma SHIVIG deter-
mination and 1 μg/ml for measurement of SHIVIG con-
tent in vaginal lavages. Plates were incubated overnight at
4°C. After blocking and washing, serially diluted, heat-
inactivated plasma samples were added to plates in tripli-
cates. Vaginal lavage samples were thawed, diluted 1:1
with blocking buffer, heat-inactivated and added to plates
in triplicate. SHIVIG was included as a standard ranging
from 0.156 to 1 μg/ml. To detect binding, plates were
incubated with rabbit anti-monkey IgG HRP-conjugated
Ab and developed with One Step Ultra TMB Substrate
(Thermo Fisher Scientific). To determine the half-life of
SHIVIG, natural logs of SHIVIG plasma levels were plot-
ted as a function of time from the end of infusion. Slopes
of the linear graphs were determined by least-squares
analysis. Half-lives were calculated as t1/2 = −(ln 2)/m.
Total IgG content in vaginal lavage fluids was assessed
by ELISA. Briefly, plates were coated with rabbit
anti-monkey IgG-whole molecule (Sigma), blocked and
probed with serially diluted vaginal lavage samples in
triplicates. After washing, bound IgG was detected with
rabbit anti-monkey IgG HRP-conjugated Ab and devel-
oped with One Step Ultra TMB Substrate. Naïve RM
(nRM) IgG served as a standard.
In vitro neutralization assays
The TZM-bl assay was performed as described [41]. In
brief, virus was added to cells in the presence of DEAE-
dextran (Sigma), washed 1× on day 1 and luminescence
was measured on day 2 using luciferase substrate Bright-
Glo (Promega).
Human PBMC-based assay was performed as descri-
bed [42]. Serially diluted SHIVIG was incubated with
virus for 1 h at 37°C. The virus/SHIVIG mixture was then
added to the cells. Supernatant aliquots were harvested
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antibodies that could interfere with the p27 assay read-
out, plates were washed 5 times on day 4. The levels of
p27 in supernatants were assayed first in wells containing
only cells plus virus. When p27 levels were in the linear
phase of increase in these control wells, neutralization was
assessed for test samples. To analyze the role of NK cells,
the same PBMC assay was run with and without NK
cells from the same donor. PBMC were depleted of
NK cells using an anti-CD56 mAb linked to magnetic
beads according to the manufacturer’s protocol (Stemcell
Technologies).
Ab-dependent cell-mediated viral inhibition (ADCVI) assay
IgG ADCVI activity was measured as described [43].
Briefly, SHIV-2873Nip-infected CEM.NKr.CCR5 target
cells were incubated with SHIVIG or HIVIG (IgG from
a pool of HIV-positive donors) and with fresh PBMC
effector cells from normal human donors (effector-
to-target cell [E:T] ratio of 10:1). Cells were washed to
remove Ab on day 4. On day 7, supernatants were
assayed for p27 by ELISA. IgG from naïve RM and IVIG
(IgG from a pool of healthy donors) were used as nega-
tive controls. Percent virus inhibition was calculated
with regards to the value obtained with the negative
control used at the same concentration as described
[43]. All samples were assayed in triplicates.
Ab-dependent cell-mediated cytotoxicity (ADCC) assay
Measurement of ADCC activity was performed as de-
scribed [44]. Briefly, target CEM-NKr cells were coated
with HIV-196ZM651 gp120 clade C. Human PBMC served
as effectors and were used at an effector to target (E:T)
ratio of 50:1. ADCC titers are defined as the reciprocal
dilution at which the % killing was greater than the
mean % killing of the negative controls plus three stand-
ard deviations. SHIVIG-derived Fab-fragments were
used as a negative control.
Complement-mediated Ab-dependent enhancement
(C’-ADE) assay
Viruses used were all clade C. Env genes from SHIV-
2873Ni, SHIV-2873Nipd and SHIV-1157ipEL were cloned
into the pNL-LucR.T2A vector containing Renilla lucifer-
ase gene inserted into pNL4-3 DNA [45]. Virus stocks
were produced in 293 T cells (NL-LucR-2873Ni, NL-LucR-
2873Nipd and NL-LucR-1157ipEL) or human PBMC
(HIV-C strains Ce1086 and Du151). C’-ADE of virus infec-
tion was measured in SupT1.R5 cells as described [37].
Virus was incubated with serial dilutions of SHIVIG or
nRM IgG in duplicates in the presence of 10% fresh
human serum as source of complement (Sigma) for 1 h
at 37°C. As control, SHIVIG was also assayed in the
presence of 10% human serum heat-inactivated (56°C, 1 h)to destroy complement activity. Percent neutralization was
determined by calculating the difference in average relative
luminescence units (RLU) between test wells (cells +
serum + virus) and cell control wells (cells only), dividing
this result by the difference in average RLU between virus
control (cell + virus) and cell-control wells, subtracting
from 1 and multiplying by 100. Negative values are indica-
tive of infection-enhancement.Single-genome analysis (SGA)
The 570 base-pair env fragment spanning V1/V2 was
amplified as described [46]. In brief, total RNA was ex-
tracted and purified from RM plasma using QIAamp viral
RNA kit (Qiagen, Valencia, CA). Reverse transcription
was performed using the Superscript III kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions using SHIV-2873Nip env-specific primers. The
cDNA was serially diluted and dispersed in 96-well
plates to identify a dilution constituting <30% of the total
number of PCR-positive wells as described [47]. Nested
PCR was performed on the cDNA to amplify the 570 bp
env fragment. The following primers were used; for the
first round forward primer (F): 5′-ATGAGAGTGAAG
GAGAAATATCAGCACTTTGTGGAGA-3′ and reverse
primer (R): 5′-TTCCTCATCTATATCATCCATATTTTG
TTTTCTGTA-3′. For the second round F: 5′-GGTACCT
GTGTGGAAAGAAGCAAAAACTACTCTAT-3′ and R:
5′-GGCTACCATTTAACAATAGTTGAGTTGACACCA
CT-3′. PCR conditions and reagents were used as descri-
bed [46]. Correctly sized amplicons were identified by aga-
rose gel electrophoresis and sequenced using env-specific
primers. All sequences were quality checked, analyzed for
diversity, viral recombination, PCR and sequencing errors
as described [46]. Finally, phylogenetic trees were cons-
tructed and the number of variants was estimated.Statistical analysis
Mean times to first or peak viremia as well as peak
viremia levels were calculated for each SHIVIG group.
Distribution assumptions of the outcomes were exam-
ined graphically and used to determine the appropriate
models for statistical analyses. Generalized linear models
were used to compare the outcomes between the control
and SHIVIG-recipient groups assuming either a Poisson
or negative binomial distribution, as appropriate, with
log-transformation. Furthermore, the AUC was calculated
for each animal, and group comparisons of log-transformed
AUCs were conducted via one-way ANOVA. Adjustments
for multiple comparisons were incorporated, as necessary.
Additionally, secondary outcomes analyses were conducted
within MHC and TRIM5α-resistant genotypes, as numbers
allowed. All analyses were conducted using StataMP
11.0 (StataCorp LP, College Station, TX).
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